Carcinoid Tumor Global Market Report 2025

Description

A carcinoid tumor is a rare, slow-growing neuroendocrine tumor that typically develops in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms vary depending on the tumor's location and whether it secretes hormones, potentially leading to carcinoid syndrome.

The primary types of carcinoid tumors include gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other disease types. Gastrointestinal neuroendocrine tumors (GI NETs) arise from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatment options include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered via oral and parenteral routes. These treatments are distributed through both online and offline channels and are utilized by hospitals, clinics, academic institutions, and research organizations.

The carcinoid tumor market research report is one of a series of new reports from The Business Research Company that provides carcinoid tumor market statistics, including the carcinoid tumor industry global market size, regional shares, competitors with the carcinoid tumor market share, detailed carcinoid tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. This carcinoid tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.61 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the rising incidence of neuroendocrine tumors, increased awareness of rare cancers, improvements in healthcare infrastructure, the availability of targeted therapies, and the expansion of clinical trials for new treatment options.

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth during the forecast period can be attributed to the rising demand for personalized medicine, a greater focus on early detection and diagnosis, increased adoption of minimally invasive surgeries, expanding research on novel therapies, and the growing use of molecular targeted therapies. Key trends expected in this period include the integration of AI and machine learning in diagnostics, a shift toward combination therapies, the expansion of telemedicine and remote monitoring, a focus on patient-centric care, and increased collaborative research efforts.

The increasing prevalence of obesity is driving the growth of the carcinoid tumor market. Obesity, characterized by a body mass index (BMI) of 30 or higher, is rising due to factors such as poor dietary habits, lack of physical activity, and excessive consumption of processed foods. This condition promotes chronic inflammation, insulin resistance, and the secretion of growth factors that contribute to tumor development, including carcinoid tumors. For example, according to the Centers for Disease Control and Prevention (CDC), in 2022, 22 U.S. states reported an adult obesity rate of 35% or higher, up from 19 states in 2021. As obesity rates continue to rise, the incidence of obesity-related cancers, including carcinoid tumors, is expected to increase, further expanding the market.

Advancements in neuroendocrine tumor detection are also playing a crucial role in market growth. Companies are developing innovative diagnostic tools, such as fully automated chromogranin A (CgA) tests, to enhance early detection and improve treatment outcomes. In October 2023, Thermo Fisher Scientific received FDA clearance for the Thermo Scientific B*R*A*H*M*S CgA II KRYPTOR immunoassay, the first FDA-approved chromogranin A test. This fully automated test measures CgA levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), helping monitor tumor progression and assess treatment efficacy. By utilizing TRACE technology, the test provides precise results in under 30 minutes, replacing manual laboratory-developed tests and improving diagnostic accuracy and efficiency.

In April 2022, SERB Pharmaceuticals acquired the European commercialization rights for Xermelo (telotristat ethyl) from Ipsen. Xermelo is a treatment for carcinoid syndrome diarrhea, a symptom of carcinoid tumors. This acquisition strengthens SERB's portfolio of treatments for rare diseases and expands access to improved therapeutic options outside the U.S. and Japan. Ipsen, a France-based biopharmaceutical company, continues to focus on developing treatments for carcinoid syndrome and other rare cancers, contributing to the overall growth of the market.

Major players in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., and Dauntless Pharmaceuticals Inc.

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in carcinoid tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carcinoid tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carcinoid Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carcinoid tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carcinoid tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carcinoid tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types
2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Online Channel; Offline Channel
5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations
Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33993

1. Executive Summary

2. Carcinoid Tumor Market Characteristics

3. Carcinoid Tumor Market Trends And Strategies

4. Carcinoid Tumor Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Carcinoid Tumor Growth Analysis And Strategic Analysis Framework

5.1. Global Carcinoid Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Carcinoid Tumor Market Growth Rate Analysis
5.4. Global Carcinoid Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Carcinoid Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Carcinoid Tumor Total Addressable Market (TAM)

6. Carcinoid Tumor Market Segmentation

6.1. Global Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastrointestinal Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
Lung Neuroendocrine Tumor
Other Disease Types
6.2. Global Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Octreotide
Lanreotide
Telotristat ethyl
Capecitabine (Xeloda)
5-Fluorouracil (5-FU)
Doxorubicin (Adriamycin)
Etoposide (VP-16)
Dacarbazine (DTIC)
Streptozocin
Other Treatments
6.3. Global Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Carcinoid Tumor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Channel
Offline Channel
6.5. Global Carcinoid Tumor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital And Clinics
Academic Institutions
Research Organizations
6.6. Global Carcinoid Tumor Market, Sub-Segmentation Of Gastrointestinal Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Bowel Neuroendocrine Tumors
Colorectal Neuroendocrine Tumors
Appendiceal Neuroendocrine Tumors
6.7. Global Carcinoid Tumor Market, Sub-Segmentation Of Pancreatic Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulinoma
Non-insulinoma
Glucagonoma
6.8. Global Carcinoid Tumor Market, Sub-Segmentation Of Lung Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Typical Carcinoid Tumors
Atypical Carcinoid Tumors
6.9. Global Carcinoid Tumor Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Thymic Neuroendocrine Tumors
Ovarian Neuroendocrine Tumors

7. Carcinoid Tumor Market Regional And Country Analysis

7.1. Global Carcinoid Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Carcinoid Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Carcinoid Tumor Market

8.1. Asia-Pacific Carcinoid Tumor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Carcinoid Tumor Market

9.1. China Carcinoid Tumor Market Overview
9.2. China Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Carcinoid Tumor Market

10.1. India Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Carcinoid Tumor Market

11.1. Japan Carcinoid Tumor Market Overview
11.2. Japan Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Carcinoid Tumor Market

12.1. Australia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Carcinoid Tumor Market

13.1. Indonesia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Carcinoid Tumor Market

14.1. South Korea Carcinoid Tumor Market Overview
14.2. South Korea Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Carcinoid Tumor Market

15.1. Western Europe Carcinoid Tumor Market Overview
15.2. Western Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Carcinoid Tumor Market

16.1. UK Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Carcinoid Tumor Market

17.1. Germany Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Carcinoid Tumor Market

18.1. France Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Carcinoid Tumor Market

19.1. Italy Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Carcinoid Tumor Market

20.1. Spain Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Carcinoid Tumor Market

21.1. Eastern Europe Carcinoid Tumor Market Overview
21.2. Eastern Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Carcinoid Tumor Market

22.1. Russia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Carcinoid Tumor Market

23.1. North America Carcinoid Tumor Market Overview
23.2. North America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Carcinoid Tumor Market

24.1. USA Carcinoid Tumor Market Overview
24.2. USA Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Carcinoid Tumor Market

25.1. Canada Carcinoid Tumor Market Overview
25.2. Canada Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Carcinoid Tumor Market

26.1. South America Carcinoid Tumor Market Overview
26.2. South America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Carcinoid Tumor Market

27.1. Brazil Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Carcinoid Tumor Market

28.1. Middle East Carcinoid Tumor Market Overview
28.2. Middle East Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Carcinoid Tumor Market

29.1. Africa Carcinoid Tumor Market Overview
29.2. Africa Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Carcinoid Tumor Market Competitive Landscape And Company Profiles

30.1. Carcinoid Tumor Market Competitive Landscape
30.2. Carcinoid Tumor Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Carcinoid Tumor Market Other Major And Innovative Companies

31.1. Abbott Laboratories
31.2. Novartis AG
31.3. GlaxoSmithKline plc
31.4. Eli Lilly and Company
31.5. Siemens Healthineers AG
31.6. Boston Scientific Corporation
31.7. Boehringer Ingelheim International GmbH
31.8. Catalent Inc
31.9. Ipsen S.A.
31.10. Exelixis Inc
31.11. Novocure Limited
31.12. Hutchison MediPharma Limited (A subsidiary of HUTCHMED)
31.13. Tarveda Therapeutics Inc.
31.14. Lexicon Pharmaceuticals Inc.
31.15. Dauntless Pharmaceuticals Inc.

32. Global Carcinoid Tumor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Carcinoid Tumor Market

34. Recent Developments In The Carcinoid Tumor Market

35. Carcinoid Tumor Market High Potential Countries, Segments and Strategies

35.1 Carcinoid Tumor Market In 2029 - Countries Offering Most New Opportunities
35.2 Carcinoid Tumor Market In 2029 - Segments Offering Most New Opportunities
35.3 Carcinoid Tumor Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer